BpOmpW antigen administered with CAF01 adjuvant stimulates comparable T cell responses to Sigma adjuvant system

TL;DR

Researchers found that the BpOmpW vaccine with CAF01 adjuvant triggers strong immune responses in mice, potentially offering protection against melioidosis.

Contribution

The study shows that CAF01 adjuvant with BpOmpW vaccine induces robust Th1, Th17, and Th2 immune responses in mice.

Findings

BpOmpW with CAF01 adjuvant stimulates strong IFN-γ responses in CD4+, CD8+, and NKT cells.

The vaccine formulation elicits Th1, Th17, and Th2 immune responses, indicating potential protection against melioidosis.

The combination is effective for protecting susceptible populations, including those with type 2 diabetes.

Abstract

There are no licensed vaccines to protect vulnerable populations from the potentially fatal tropical infection, melioidosis, despite its causative agent, Burkholderia pseudomallei, being endemic in tropical and subtropical regions. A promising vaccine candidate, BpOmpW protected mice from melioidosis infection for up to 81 days and stimulated robust interferon gamma responses in CD4+, CD8+, NK and NKT cells. In order to progress to human studies, selection of an adjuvant with an acceptable human safety profile that stimulates appropriate correlates of protection is essential. Here we demonstrate that the CAF01 vaccine adjuvant elicits optimal immune correlates of protection when administered with our BpOmpW vaccine. Specifically, we demonstrate that CAF01 administered with BpOmpW elicits robust Th1 responses, with potent IFN-γ responses in CD4+ and CD8+ T cells and NKT cells, in addition to Th17 and Th2 responses. This formulation will be particularly effective in protecting susceptible populations including people with type 2 diabetes from melioidosis.

Figures